Madrigal Pharmaceuticals 于 2024 年 2 月 28 日公布第四季度收益，每股收益低于预期 8.0%，收入持平；任命 Mardi C. Dier 为首席财务官。 Madrigal Pharmaceuticals reported Q4 earnings on 28 Feb 2024, missing EPS estimate by 8.0%, with revenue remaining flat; appointed Mardi C. Dier as CFO.
Madrigal Pharmaceuticals （纳斯达克股票代码：MDGL）于 2024 年 2 月 28 日公布了第四季度收益，每股收益比预期低 8.0%，为 -5.68 美元，而不是 -5.28 美元。 Madrigal Pharmaceuticals (NASDAQ: MDGL) reported Q4 earnings on February 28, 2024, missing estimated EPS by 8.0% with $-5.68 instead of $-5.28. 收入与上年持平。 Revenue remained flat from the previous year. 该公司宣布任命 Mardi C. Dier 为首席财务官，接替 Alex Howarth。 The company announced the appointment of Mardi C. Dier as Chief Financial Officer, replacing Alex Howarth. Dier 拥有 20 多年在生物制药行业担任财务高管的经验。 Dier brings over 20 years of experience in executive financial roles in the biopharmaceutical industry.